Baer, Maria R.

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AML

Perl, A. E., Martinelli, G., Cortes, J. E., Neubauer, A., Berman, E., Paolini, S., Montesinos, P., Baer, M. R., Larson, R. A., Ustun, C., et al. (2019) · New England Journal of Medicine

Acute Myeloid Leukemia ResearchRetinoids in leukemia and cellular processes

Cited by 1,287

The Tyrosine Kinase Inhibitor Imatinib Mesylate Enhances the Efficacy of Photodynamic Therapy by Inhibiting ABCG2

Liu, W., Baer, M. R., Bowman, M. J., Pera, P., Zheng, X., Morgan, J., Pandey, R. A., & Oseroff, A. R. (2007) · Clinical Cancer Research

Photodynamic Therapy Research StudiesDrug Transport and Resistance Mechanisms

Cited by 136

Therapeutic targeting of TP53-mutated acute myeloid leukemia by inhibiting HIF-1α with echinomycin

Wang, Y., Liu, Y., Bailey, C., Zhang, H., He, M., Sun, D., Zhang, P., Parkin, B., Baer, M. R., Zheng, P., et al. (2020) · Oncogene

Acute Myeloid Leukemia ResearchCancer, Hypoxia, and Metabolism

Cited by 38

Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia

Cortes, J., Kantarjian, H., Ball, E. D., DiPersio, J., Kolitz, J. E., Fernandez, H. F., Goodman, M., Borthakur, G., Baer, M. R., & Wetzler, M. (2012) · Cancer

Acute Myeloid Leukemia ResearchCancer-related Molecular Pathways

Cited by 37

Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial

Jabbour, E., Oehler, V. G., Koller, P. B., Jamy, O., Lomaia, E., Hunter, A. M., Uspenskaya, O., Samarina, S., Mukherjee, S., Cortes, J. E., et al. (2025) · JAMA Oncology

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 33